Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer Clinical research trials and Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer. Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "V" Clinical Trials Conditions > Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer



Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

For Condition: recurrent prostate cancer,stage 3 prostate cancer
Status: No longer recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer.
Details: OBJECTIVES: - Determine the safety of glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 in patients with prostate cancer. - Determine the antibody response in patients treated with this vaccination therapy. - Assess post-immunization changes in PSA levels and other objective parameters of disease (radionuclide bone scan) in patients treated with this vaccination therapy. OUTLINE: Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50. Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression. PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 2 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed prostate cancer - Disease progression after primary surgery (radical prostatectomy) or radiotherapy with or without prior neoadjuvant androgen ablation - Minimum of 3 rising PSA values, taken at least 2 weeks apart, with more than a 50% rise in PSA level above the baseline value (1.0 ng/mL post -prostatectomy or 2.0 ng/mL post-radiotherapy) - Received prior intermittent hormonal therapy after prior primary therapy - Non-castrate levels of testosterone (more than 50 ng/mL) - Evaluable disease (by serial changes in PSA) - No radiographic evidence of metastatic disease - No active CNS or epidural tumor - No soft tissue and/or bone disease - No androgen-independence with no evidence of radiographic disease - May not be symptomatic or anticipated to develop symptoms within 6 months of study entry PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - At least 6 months Hematopoietic: - WBC at least 3,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin less than 2.0 mg/dL - SGOT less than 3 times upper limit of normal Renal: - Creatinine no greater than 2.0 mg/dL OR - Creatinine clearance at least 40 mL/min Cardiovascular: - No clinically significant cardiac disease (New York Heart Association class III or IV) Pulmonary: - No severe debilitating pulmonary disease Other: - No allergy to seafood (shellfish) - No other active malignancy within the past 5 years except nonmelanoma skin cancer - No infection requiring antibiotics - No narcotic-dependent pain - No positive stool guaiac unless associated with hemorrhoids or prior documented radiation-induced proctitis PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 4 weeks since prior chemotherapy Endocrine therapy: - See Disease Characteristics - See Chemotherapy - At least 2 weeks since change in hormonal therapy (e.g., prednisone or dexamethasone) except to maintain castrate levels of testosterone Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy - No concurrent irradiation of only measurable lesion Surgery: - See Disease Characteristics - No concurrent surgery of only measurable lesion Other: - Recovered from prior therapy - At least 8 weeks since prior suramin and/or documented plasma concentration of suramin if less than 50 micrograms/mL (replacement hydrocortisone allowed) - No other concurrent oncolytic agents - No concurrent immunosuppressive therapy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
SusanSlovin,  Study Chair,  Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
New York City,  New York,  10021
United States
 


Additional Information:
Study ID Numbers:  CDR0000069342;  NCI-G02-2064,MSKCC-01140
Study Start Date: 
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036933

Other Recurrent Prostate Cancer Studies:
1. Perifosine in Treating Patients With Recurrent Prostate Cancer

2. Bortezomib and Mitoxantrone in Treating Patients With Advanced or Metastatic Androgen-Independent Prostate Cancer

3. ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

4. Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

5. Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

Related Studies:

Other recurrent prostate cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Modify your Search

  Other recurrent prostate cancer Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103